Universal dengue virus sequences and methods of use

Patent metadata

Field	Value
Publication number	US-8993744-B2
Application number	US-201113698719-A
Country	US
Kind code	B2
Filing date	May 23, 2011
Priority date	May 21, 2010
Publication date	Mar 31, 2015
Grant date	Mar 31, 2015

Abstract

Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments (such as the E protein ectodomain and DIII domain) fused to the molecular adjuvant P28. The disclosed nucleic acid and polypeptide sequences can be used as vaccines for immunization against dengue virus infection. In some cases, the vaccine includes a virus-like particle containing the universal dengue virus E protein, or fragment thereof, or the vaccine is a DNA molecule encoding the VLP.

First claim

The invention claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a dengue virus E protein or a fragment thereof, wherein:
(a) the nucleotide sequence encoding the dengue virus E protein is at least 99% identical to SEQ ID NO: 1 or at least 99% identical to nucleotides 4-1488 of SEQ ID NO: 1;
(b) the fragment comprises the E protein ectodomain and the nucleotide sequence encoding the E protein ectodomain is at least 99% identical to nucleotides 1-1194 of SEQ ID NO: 1 or at least 99% identical to nucleotides 4-1194 of SEQ ID NO: 1; or
(c) the fragment comprises the DIII domain of the E protein and the nucleotide sequence encoding the DIII domain is at least 99% identical to SEQ ID NO: 13.

2. The isolated nucleic acid molecule of claim 1 , wherein the nucleotide sequence encoding the E protein comprises SEQ ID NO: 1.

3. The isolated nucleic acid molecule of claim 1 , wherein the nucleotide sequence encoding the E protein ectodomain comprises nucleotides 1-1194 of SEQ ID NO: 1.

4. The isolated nucleic acid molecule of claim 1 , the fragment of (b) further comprising a nucleotide sequence encoding the P28 region of complement protein C3d.

5. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises a nucleotide sequence encoding the E protein ectodomain or the E protein DIII domain and further comprises a nucleotide sequence encoding the P28 region of complement protein C3d.

6. The isolated nucleic acid molecule of claim 5 , wherein the amino acid sequence of the P28 region of complement protein C3d comprises SEQ ID NO: 21.

7. A vector comprising the isolated nucleic acid molecule of claim 1 .

8. The vector of claim 7 , further comprising a nucleic acid sequence encoding a dengue virus prM protein.

9. An isolated cell comprising the vector of claim 7 .

10. A composition comprising the nucleic acid molecule of claim 1 and a pharmaceutically acceptable carrier.

11. A method of eliciting an immune response against dengue virus in a subject, comprising administering to the subject the composition of claim 10 , thereby eliciting an immune response against dengue virus in the subject.

Assignees

• Ross Ted M
• Vasilakis Nikolaos
• Univ Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Ross Ted M
• Vasilakis Nikolaos

Classifications

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• C12N2770/24123

  Virus like particles [VLP] · CPC title

• A61K2039/55516

  Proteins; Peptides · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title